Polar Capital unveils biotechnology fund

BiotechnologyPolar Capital Holdings has launched an open-ended biotechnology Ucits fund to be managed by David Pinniger, who was recently hired from SV Life Sciences where he managed the International Biotechnology Trust. The Polar Capital Biotechnology Fund aims to achieve long-term capital growth by investing in a globally diversified portfolio of biotechnology companies. Pinniger will construct a portfolio of between 40 and 60 investments, focusing on medical innovation, with performance benchmarked against the Nasdaq Biotechnology Index. “Advances in information technology – in particular increases in computer processing power – are enabling medical science to make rapid advances in understanding the complex biology of health and disease,” Pinniger says. “In recent years, we've also seen a proliferation of tools and technologies that are enabling new ways of targeting the molecular basis of disease.” Pinniger says highly innovative products being developed by biotechnology companies are a trend that is key to managing his new fund. He adds that he will seek companies where it is believed successful development of a drug, device or diagnostic tool has the potential to transform the treatment of a disease where there is unmet medical need. The fund is available in sterling, US dollar and euro-denominated share classes. The annual management charge is 1.5% on the retail share class and 1% on the institutional share class. ©2013 funds europe

Executive Interviews

INTERVIEW: Put your money where your mouth is

Jun 10, 2016

At Kempen Capital Management, they believe portfolio managers should invest in their own funds. David Stevenson talks to Lars Dijkstra, CIO of the €42 billion manager.

EXECUTIVE INTERVIEW: ‘Volatility is the name of the game’

May 13, 2016

Axa Investment Managers chief executive officer, Andrea Rossi, talks to David Stevenson about bringing all his firm’s subsidiaries under one name and the opportunities that a difficult market...


ROUNDTABLE: Beyond the hype

Oct 13, 2016

The use of smart beta investing continues to grow. Our panel, made up of both providers and users, discusses what the strategy actually means, how it should be used and the kind of pitfalls that may arise when using this innovative investment technique.

MIFID II ROUNDTABLE: Following the direction of travel

Sep 07, 2016

Fund management firms Aberdeen and HSBC Global meet with specialist providers to speak about how the industry is evolving towards MiFID II.